A Real-World Analysis of Tyrosine Receptor Kinase Inhibitor-Related Toxicities in Cancer Treatment

Abstract

Background: This study analyzed real-world data from 2004 to 2023 to evaluate the toxicity profile of tyrosine receptor kinase (TRK) inhibitor therapy. Method: A retrospective analysis of US FDA Adverse Event Reporting System data was conducted to identify adverse events in patients receiving TRK inhibitor therapy. Result: Entrectinib demonstrated toxicities primarily in the cardiovascular and nervous systems, followed by the renal and urinary system. Common adverse effects included dizziness, renal impairment, constipation, heart failure and taste disorders. Larotrectinib induced adverse events mainly in the hepatobiliary and nervous systems, with peripheral neuropathy, myalgia, renal impairment and increased alanine aminotransferase commonly reported. Conclusion: Careful monitoring and supportive care strategies are essential for managing adverse events associated with TRK inhibitor therapy.

Keywords: :

• cancer
• FAERS
• safety
• toxicity profile
• TRK inhibitor

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.tandfonline.com/doi/suppl/10.2217/pme-2023-0072

Author contributions

W Li and K Wen: conceptualization, methodology, data curation, software and writing – review and editing; W Zhu and S Luo: visualization. The work reported in the paper has been performed by the authors, unless clearly specified in the text.

Acknowledgments

The authors appreciate the work of the FAERS database (www.fda.gov/).

Financial disclosure

The authors have no financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.

Competing interests disclosure

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

Data availability statement

The original data are available in the FAERS database (www.fda.gov/).

Ethical conduct of research

No ethics approval and written consent were needed for the secondary analysis of public data.